Slow allotypic variants of the NAT2 gene and susceptibility to early- onset Parkinson's disease

Neurology

Volumn 51, Issue 6, 1998, Pages 1587-1592

  Agundez J A G ^a   Jimenez Jimenez F J ^b   Luengo, A ^c   Molina, J A ^d   Orti Pareja M ^b   Vazquez A ^e   Ramos, F ^c   Duarte, J ^f   Coria, F ^g   Ladero, J M ^e   Alvarez Cermeno J C ^h   Benitez J ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL GENERAL DE SEGOVIA   (Spain)

^g HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DNA;

ACETYLATION; ADULT; AGED; ALLOTYPE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENOTYPE; HEREDITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PENETRANCE; PRIORITY JOURNAL;

EID: 17444452570     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.6.1587     Document Type: Article

References (28)

1. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement disorders. New York: McGraw-Hill, 1997:137-152.
2. Jiménez-Jiménez FJ. Epidemiología de la enfermedad de Parkinson. In: Obeso JA, Tolosa E, Grandas F, eds. Tratado sobre la enfermedad de Parkinson. Madrid: Luzán 5 Ediciones, 1997:71-88.
3. Polymeropoulos M, Higgins J, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-23. Science 1996;274:1197-1199.
4. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997;60:588-596.
5. Diederich N, Hilger C, Goetz CG, et al. Genetic variability of the CYP 2D6 gene is not a factor for sporadic Parkinson's disease. Ann Neurol 1996;40:463-465.
6. Gasser T, Muller-Myshok B, Supala A, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520.
7. McCann SJ, Pond SM, James KM, Le Couteur DG. The association between polymorphisms in the cytochrome P450 2D6 gene and Parkinson's disease: a case-control study and a meta-analysis. J Neurol Sci 1997;153:50-53.
8. Fonne-Pfister R, Bargetzi MJA, Meyer UA. MPTP the neurotoxin inducing Parkinson's disease, is a potent inhibitor of human and rat P450 enzymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987;48:1144-1150.
9. Jiménez-Jiménez FJ, Tabernero C, Mena MA, et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J Neurochem 1991;57:81-87.
10. Martínez C, Agúndez JAG, Gervasini G, Martín R, Benítez J. Tryptamine: a potential endogenous substrate for CYP2D6. Pharmacogenetics 1997;7:85-93.
11. Bandmann O, Vaughan J, Marsden CD, Wood NW. Association of slow acetylation genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997;350:1136-1139.
12. Gasser T, Wszolek ZK, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994;36:387-396.
13. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-168.
14. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-296.
15. Agúndez JAG, Jiménez-Jiménez FJ, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298.
16. Ladero JM, Jiménez-Jiménez FJ, Benítez J, et al. Acetylator polymorphism in Parkinson's disease. Eur J Clin Pharmacol 1989;37:391-393.
17. Igbokwe E, Ogunniyi A, Osuntokun B. Xenobiotic metabolism in idiopathic Parkinson's disease in Nigerian Africans. East Afr Med J 1993;70:807-809.
18. Peters L, Steventon G, Green S, Struman S, Waring R, Williams A. D-penicillamine metabolism in neurodegenerative disease: an in vitro/in vivo sulphydryl methylation study. Xenobiotica 1994;24:1013-1020.
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
20. Agúndez JAG, Martínez C, Olivera M, Ladero JM, Benítez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996;6:423-428.
21. Agúndez JAG, Rodriguez I, Olivera M, et al. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing 1997;26:147-151.
22. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15.
23. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986;73: 320-322.
24. Agúndez JAG, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994;56:202-209.
25. Martínez C, Agúndez JAG, Olivera M, Martín R, Ladero JM, Benítez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995;5:207-214.
26. Bulpitt CJ. Confidence intervals. Lancet 1987;1:494-497.
27. Steventon GB, Heafield MTE, Waring RH, Path MRC, Williams AC. Xenobiotic metabolism in Parkinson's disease. Neurology 1989;39:883-887.
28. De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord 1996;11:17-23.